BAFNAPH

Bafna Pharmaceuticals Share Price

₹80.00 +0.79 (1%)

28 Dec, 2024 02:20

SIP TrendupStart SIP in BAFNAPH

Start SIP

Performance

  • Low
  • ₹78
  • High
  • ₹82
  • 52 Week Low
  • ₹73
  • 52 Week High
  • ₹113
  • Open Price₹80
  • Previous Close₹79
  • Volume3,851

Investment Returns

  • Over 1 Month + 2.16%
  • Over 3 Month -4.65%
  • Over 6 Month + 6%
  • Over 1 Year -15.75%
SIP Lightning

Smart Investing Starts Here Start SIP with Bafna Pharmaceuticals for Steady Growth!

Invest Now

Bafna Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 465.2
  • PEG Ratio
  • -4.8
  • Market Cap Cr
  • 189
  • P/B Ratio
  • 2.3
  • Average True Range
  • 3.27
  • EPS
  • 0.32
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.1
  • RSI
  • 47.92
  • MFI
  • 50.49

Bafna Pharmaceuticals Financials

Bafna Pharmaceuticals Technicals

EMA & SMA

Current Price
₹80.00
+ 0.79 (1%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹80.64
  • 50 Day
  • ₹80.83
  • 100 Day
  • ₹81.95
  • 200 Day
  • ₹84.69

Resistance and Support

80 Pivot Speed
  • R3 85.83
  • R2 83.89
  • R1 81.94
  • S1 78.05
  • S2 76.11
  • S3 74.16

What's your outlook on Bafna Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bafna Pharmaceuticals has an operating revenue of Rs. 143.45 Cr. on a trailing 12-month basis. An annual revenue growth of 32% is outstanding, Pre-tax margin of 5% is okay, ROE of 9% is fair but needs improvement. The company has a reasonable debt to equity of 13%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 18 which is a POOR score indicating inconsistency in earnings, a RS Rating of 29 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bafna Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-11 Quarterly Results
2024-08-13 Quarterly Results
2024-05-29 Audited Results
2024-02-12 Quarterly Results
2023-11-09 Quarterly Results

Bafna Pharmaceuticals F&O

Bafna Pharmaceuticals Shareholding Pattern

88.3%
7.69%
4.01%

About Bafna Pharmaceuticals

  • NSE Symbol
  • BAFNAPH
  • BSE Symbol
  • 532989
  • ISIN
  • INE878I01022

Similar Stocks to Bafna Pharmaceuticals

Bafna Pharmaceuticals FAQs

Bafna Pharmaceuticals share price is ₹80 As on 28 December, 2024 | 02:06

The Market Cap of Bafna Pharmaceuticals is ₹189.3 Cr As on 28 December, 2024 | 02:06

The P/E ratio of Bafna Pharmaceuticals is 465.2 As on 28 December, 2024 | 02:06

The PB ratio of Bafna Pharmaceuticals is 2.3 As on 28 December, 2024 | 02:06

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23